1. Step 9
1.1. Review session 3
1.2. visualize the data and theory
1.2.1. mycobacterial TB
1.2.2. sensitive to rifampicine , isoneside, ethanbutol
1.3. 20 minutes
2. Step 10
2.1. Management (for the individual)
2.2. based on:
2.2.1. patient's problem list
2.2.2. treatment
2.2.2.1. initial treatment
2.2.2.1.1. 2 months
2.2.2.1.2. three test
2.2.2.2. continuation phase
2.2.2.2.1. 4-7 months
2.2.2.2.2. test every month
2.2.2.3. should in combination
2.2.2.4. DOTS for at least two months
2.2.2.4.1. testing for HIV liver function test
2.2.2.5. combination of drugs to avoid resistance
2.2.2.6. if the result after two months positive and the initial x-ray has cavities it extends the continuation phase for nine months
2.2.2.7. three drugs should be resistance to call it resistance
2.2.2.8. with second line treatment : the cost is high
2.2.2.9. streptomycine for old people
2.2.2.10. surgical is needed if there is multidrug resistance, but not preferable
2.2.2.11. regular chick urine to make sure that he is taking his drug
2.2.3. options
2.2.3.1. first line
2.2.3.1.1. isoniazed
2.2.3.1.2. rifampicine
2.2.3.1.3. ethambutol
2.2.3.1.4. pyrazinamide
2.2.3.1.5. nausea and loss of appetite
2.2.3.1.6. 50mg isoneside , 120 mg rifampin , 300 mg pyrazinmide
2.2.3.1.7. consider the weight
2.2.4. regime
2.2.4.1. once daily or twice a week
2.2.4.2. if its fully sensative no need to ethabutol
2.2.4.3. in extra pulmonary more time is needed
2.2.4.4. multidrug resistance for at least 18 months
2.2.4.5. if it is not effective either elongate or restart
2.2.5. qualifying factors
2.2.6. evidence
2.3. Prevention (for the population)
2.3.1. isolation
2.3.2. BCG vaccination
2.3.2.1. recommended for children
2.3.2.2. most neonatal take it
2.3.2.3. recommended in areas that have high TB incidence
2.3.3. opens windows
2.3.4. protective measures for people close to TB patient
2.3.5. finishing the entire medication course
2.3.6. high risk for children under thae age of 4 years
2.3.7. hospital policy
2.3.8. check co-workers and close contact
2.3.9. educate the patient about his disease capabilities